Much of cell behavior is governed by the actions of biomolecular condensates: building block molecules that glom together and scatter apart as needed. Biomolecular condensates constantly shift their ...

Among participants who met the core RESTORE-ALS Trial criteria (e.g., baseline serum NfL > 33 pg/mL, TRICALS risk score range between –6.5 and –2.5, baseline slow vital capacity > 60%, and symptom ...

Columnist Dagmar Munn says she has often felt out of place in the ALS community because of the slower pace of her disease ...

Clene (CLNN) and its subsidiary, Clene Nanomedicine announced new evidence from a cross-regimen, post hoc analysis of long-term survival in ...

Clene, Inc. (Nasdaq: CLNN) and its subsidiary, Clene Nanomedicine, Inc., a clinical-stage biopharmaceutical company focused on revolutionizing the treatment ...

Noon, is tackling ALS and other neurological disorders with a bold, multi-targeted approach. Fueled by a personal encounter ...

A myotrophic lateral sclerosis (ALS) is a progressive neurodegenerative disease that affects muscle control, and most ...

By Leah ShafferMuch of cell behavior is governed by the actions of biomolecular condensates: building block molecules that glom together and scatter ...

Per the deal terms, IONS will receive an upfront payment of $280 million from Ono. It is also eligible for milestone payments of up to $660 million.

BenevolentAI, ("BenevolentAI" or "the Company") (Euronext Amsterdam: BAI), a pioneer in AI-driven drug discovery, today announces that: All resolutions proposed at its Extraordinary General Meeting ...

Bancography, a financial services consulting firm, today released its annual research report, Outlook 2025: Industry Trends and the Challenges Ahead. It examines statistics on deposit growth, ...